METHOD FOR PRODUCING GAMMA -GLUTAMYL-VALYL-GLYCINE CRYSTAL
申请人:AJINOMOTO CO., INC.
公开号:US20150361133A1
公开(公告)日:2015-12-17
The present invention provides a method for efficiently producing a γ-glutamyl-valyl-glycine crystal. Specifically, the present invention provides a method for producing a γ-glutamyl-valyl-glycine crystal, which includes the steps of: preparing a mixed solution of valyl-glycine or a salt thereof and γ-glutamyl-valyl-glycine, wherein the mixed solution contains valyl-glycine or the salt thereof in an amount of 20 mass % or more relative to the mass of γ-glutamyl-valyl-glycine; adjusting the amount of valyl-glycine or the salt thereof in the prepared mixed solution to 0.1 mass % or more and less than 20 mass % relative to the mass of γ-glutamyl-valyl-glycine to prepare a γ-glutamyl-valyl-glycine solution; and subjecting the γ-glutamyl-valyl-glycine solution to a crystallization procedure to produce the γ-glutamyl-valyl-glycine crystal.
A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.
Enzymatic Synthesis of γ‐Glutamyl Dipeptides Catalysed by Mutant
<i>E. coli</i>
γ‐Glutamyltransferases
作者:Marco Rabuffetti、Giovanna Speranza、Cinzia Calvio、Carlo F. Morelli
DOI:10.1002/ejoc.202200907
日期:2022.11.18
identified inside the active site of E. coli γ-glutamyltransferase, putatively involved in acceptor substrate binding. Point-mutation of these residues afforded two mutant enzymes with altered catalytic properties. Mutant T413L showed a very promising transpeptidation-to-hydrolysis ratio up to 20 : 1. The two mutants were tested as biocatalysts for the enzymatic synthesis of γ-glutamyl dipeptides with flavor-enhancer
METHOD FOR PRODUCING -GLUTAMYL-VALYL-GLYCINE CRYSTAL
申请人:Ajinomoto Co., Inc.
公开号:EP2883960A1
公开(公告)日:2015-06-17
The present invention provides a method for efficiently producing a γ-glutamyl-valyl-glycine crystal. Specifically, the present invention provides a method for producing a γ-glutamyl-valyl-glycine crystal, which includes the steps of: preparing a mixed solution of valyl-glycine or a salt thereof and γ-glutamyl-valyl-glycine, wherein the mixed solution contains valyl-glycine or the salt thereof in an amount of 20 mass% or more relative to the mass of γ-glutamyl-valyl-glycine; adjusting the amount of valyl-glycine or the salt thereof in the prepared mixed solution to 0.1 mass% or more and less than 20 mass% relative to the mass of γ-glutamyl-valyl-glycine to prepare a γ-glutamyl-valyl-glycine solution; and subjecting the γ-glutamyl-valyl-glycine solution to a crystallization procedure to produce the γ-glutamyl-valyl-glycine crystal.
TRYPTOPHAN AS A BIOMARKERS FOR KIDNEY FUNCTION AND METHODS USING THE SAME
申请人:Metabolon, Inc.
公开号:EP3410115A1
公开(公告)日:2018-12-05
Biomarkers of kidney function and methods for using said biomarkers for assessing kidney function, monitoring kidney function, diagnosing acute kidney injury, and diagnosing chronic kidney disease are provided. Also provided are suites of small molecule entities as biomarkers for chronic kidney disease.